

THE EFFECT OF
LONG TERM TREATMENT
WITH DICOUMAROL
IN
MYOCARDIAL INFARCTION

A CONTROLLED CLINICAL STUDY

BY

CHRISTOPHER JUEL BJERKELUND, M.D.

Senior Assistant Physician, Medical Department VIII,
Ullevål Hospital Oslo, Norway

GRUNE & STRATTON, INC.
NEW YORK LONDON

THE EFFECT OF
LONG TERM TREATMENT
WITH DICOUMAROL
IN
MYOCARDIAL INFARCTION

A CONTROLLED CLINICAL STUDY

BY

CHRISTOPHER JUEL BJERKELUND, M.D.

Senior Assistant Physician, Medical Department VIII,
Ullevål Hospital Oslo, Norway

GRUNE & STRATTON, INC.
NEW YORK LONDON

FROM: THE MEDICAL DEPT. VIII, ULLEVÅL HOSPITAL, OSLO, NORWAY
HEAD: CARL MÜLLER, M.D., PROFESSOR OF INTERNAL MEDICINE,
UNIVERSITY OF OSLO

All Rights Reserved, 1957
Made and Printed in Norway
by Oslo University Press

Kirstes Boktrykkeri, Oslo

Contents.

Chapter I

Background to this study	13
------------------------------------	----

Chapter II

The problem of the investigation. Theoretical and practical considerations for the solution of the problem	15
Presentation of the problem and primary considerations	15
Pathogenesis of coronary occlusion	15
Incidence of thrombosis as the cause of coronary occlusion	16
Appositional growth of the thrombus	17
Recanalisation of thrombus	18
The role of intimal bleeding in the pathogenesis	18
Other pathogenetic factors	20
Is thrombosis a pathogenetic factor in the development of atherosclerosis?	20
Prognosis after survival from acute myocardial infarction	22
Discussion of previous investigations on the long term prognosis after myocardial infarction	22
Cause of death in coronary disease	25
Practical conditions for the investigation	26
Possibilities for collecting material	26
Basis for control of treatment with dicoumarol	27
Summary and conclusion	29

Chapter III

Previous publications on long term anticoagulant therapy	31
Account of previous publications	31
Haemorrhagic complications	38
Summary and conclusion	41

Chapter IV

Planning the investigation	43
Allotting patients to the treated and control groups	43
Choice of statistical method of selection	43
Question of the use of placebos	45
Age limit	46
Size of treated and control groups	46
Patients who had to be withdrawn from the final investigation	47
Clinical investigation of the patients while in hospital	47
Case history	47
Clinical examination	48
Investigations	48

Diagnosis of the acute infarct—diagnostic criteria	48
Investigation technique	49
Quantitative estimation of prothrombin-proconvertin. Owren's PP method	49
Quantitative estimation of total serum cholesterol	52
Liver function tests	52
Electrocardiographic technique	53
Radiological examination of the heart	53
Summary and conclusion	53

Chapter V

Selection of patients for the investigation	55
The total material—section A	55
Patients excluded from the controlled clinical trial according to plan	56
Additional patients excluded from the controlled clinical trial	57
Summary	59

Chapter VI

More details about the material. Statistical examination of the comparability of the treated and control groups	60
Introductory remarks	60
General characteristics of the sample	61
Age distribution	61
Sex distribution	62
Race	62
Geography	62
Social standing	62
Height and weight	63
Conditions in the previous history considered to be of significance for the prognosis	64
Angina pectoris	64
Myocardial infarction	64
Hypertension	65
Heart failure	66
Valvular disease	66
Cerebral vascular accident	67
Obliterating arteriosclerosis and thromboangiitis obliterans	67
Diabetes mellitus	68
Course of the recorded acute infarct	68
Prodromal symptoms of infarction	69
Attack at rest or on exertion?	69
Interval between attack and admission	70
Pain	70
Vomiting	71
Dyspnoea	71
Heart failure	72
Pericardial friction rub	73
Gallop rhythm	73
Maximum pulse rate in the first week	73
Blood pressure	74

Shock	77
Position of the myocardial infarct on electrocardiography	78
Arrhythmias and conduction disturbances	79
Maximum temperature during the first week	80
Leucocyte count	80
Blood sedimentation rate	81
Fasting blood sugar	82
Serum cholesterol, xanthelasma, xanthomatous nodules	83
Cardiac volume estimated radiologically	84
Summary and conclusion	86

Chapter VII

Treatment of the acute infarct during the first month	88
Medical care	88
Nursing	89
General care	89
Medical and dietetic treatment	90
Use of digitalis	90
Salt restriction	90
Restriction of calories	91
Use of oxygen	91
Treatment of shock by transfusion	91
Use of dicoumarol	91
Duration of treatment with dicoumarol in the control group	92
Use of heparin	93
Complications during treatment of the acute infarct	93
Haemorrhagic complications	94
Thromboembolic complications	94
Complications with no direct relationship to the heart or to anticoagulants	95
Length of time in hospital	96
Condition on discharge	97
Summary and conclusion	97

Chapter VIII

Observation and treatment in the ambulant phase. Length of observation	99
Management of the control group	99
Management of the treated group	101
Recording and filing the data	102
Management of treatment with dicoumarol	102
Length of observation	105
Summary and conclusion	106

Chapter IX

Intensity of the anticoagulant therapy as judged by the PP values recorded during the observation time	108
Introductory remarks	108
Relationship between the PP values recorded and the PP level over the total period of treatment	109
Interruptions in treatment	111

Type of material	112
Influence of the problem under investigation on the treatment	112
The PP values recorded	113
PP level in each individual patient	115
Anticoagulant therapy in the control group	117
Summary and conclusion	118

Chapter X

Recurrent infarction during the observation period.

Statistical analysis of the incidence of recurrence	120
Thromboembolic episodes in cases of myocardial infarction	120
The clinical diagnosis of recurrent infarction	121
Relationship between recurrent infarction and sex	124
Relationship between recurrent infarction and age	125
Statistical examination of the incidence of recurrent infarction	126
Relationship between incidence of recurrent infarction and other factors of cardiological significance	132
Previous angina pectoris	133
Previous infarction	134
Blood pressure	134
Size of the heart	136
Body weight	137
Summary	138

Chapter XI

Mortality during the observation period. Statistical analysis of the mortality	139
Information about the deaths	139
Causes of death	140
Relationship between mortality and sex	143
Relationship between mortality and age	144
Statistical examination of the mortality	145
Relationship between mortality and different factors of cardiological significance	151
Previous angina pectoris	151
Previous infarction	152
Blood pressure	152
Size of the heart	153
Body weight	153
Summary	155

Chapter XII

PP level in relation to recurrent infarction and sudden death	156
Summary and conclusion	159

Chapter XIII

Haemorrhagic complications	160
Observation of haemorrhages	160
Number of haemorrhages, type and degree of severity	160
Relationship between haemorrhages and PP values	163

Haemorrhages with a contributory local cause	164
Treatment of the haemorrhagic complications	166
Haemorrhagic complications in the control group	167
Summary and conclusion	169

Chapter XIV

Investigation of liver function during long term treatment with dicoumarol	170
Summary and conclusion	171

Chapter XV

Supplementary comparison of the treated and control groups during the observation period. Mode of life and morbidity	172
Diet, alcohol, tobacco	172
Ability to work and type of work	173
Frequency and duration of admissions to hospital	173
Heart failure	175
Angina pectoris	176
Increase in size of the heart	178
Electrocardiographic investigation	179
Extra-cardiac thromboembolic complications	180
Summary and conclusion	181

Chapter XVI

Medical and psychological significance of regular supervision of patients after myocardial infarction	182
------------------------------------------------------------------------------------------------------------------	-----

Chapter XVII

Autopsy findings	184
Introductory remarks	184
Number and distribution of post mortems. Technique	184
Characteristics of post mortem cases	185
Post mortem verification of the original acute infarct	186
Causes of death	186
Thromboembolic phenomena	189
Haemorrhagic phenomena	190
Cardiac hypertrophy. Weight of heart	191
Summary and conclusion	191

Chapter XVIII

Discussion and conclusion	193
General summary	198
Appendix	204
References	206

THE EFFECT OF
LONG TERM TREATMENT
WITH DICOUMAROL
IN
MYOCARDIAL INFARCTION

A CONTROLLED CLINICAL STUDY

BY

CHRISTOPHER JUEL BJERKELUND, M. D.

Senior Assistant Physician, Medical Department VIII,
Ullevål Hospital Oslo, Norway

147.24+14.15:
8131

GRUNE & STRATTON, INC.
NEW YORK LONDON

FROM: THE MEDICAL DEPT. VIII, ULLEVÅL HOSPITAL, OSLO, NORWAY
HEAD: CARL MÜLLER, M. D., PROFESSOR OF INTERNAL MEDICINE,
UNIVERSITY OF OSLO

All Rights Reserved, 1957
Made and Printed in Norway
by Oslo University Press

TO
CARL MÜLLER

Preface.

The investigations presented in this study were carried out in Ullevål Hospital, Department VIII in the period 1950–1956 while I was employed as Assistant Physician there.

I would like to express my heartfelt gratitude to the head of the Department, Professor Carl Müller for his unfailing interest in my work, for encouragement and valuable advice. His teaching and great experience in cardiology have been a constant source of inspiration.

I am greatly indebted to the former head of Department VII, Professor R. Hatlehol and the head of Department IX, Professor H. J. Ustvedt for their friendliness and permission to make use of the material from their departments.

I also wish to thank my former chief Professor P. A. Owren. The basic knowledge of blood coagulation and anticoagulant therapy which I was taught as assistant and research fellow in his department and laboratory was a necessary prerequisite for this investigation.

I am particularly grateful to Professor E. Sverdrup for invaluable help and advice in the statistical investigation of my observations. His genuine interest in my problems was a real encouragement and inspiration during the preparation of this study.

I am also indebted to Dr. P. Amundsen in the Roentgen Department in Ullevål Hospital who kindly carried out all the radiological examinations and to the head of the Department of Pathology, Dr. E. Hval for his permission to make use of the autopsy reports.

Special thanks are due to Miss Sigrid Efjestad and Miss Inga Bjørnstad, who were my assistants in the laboratory from the very beginning of the investigation, for their dependable and accurate work, their kindness and unfailing loyalty through many years. I also want to thank their colleagues in the medical laboratories for valuable assistance and the nurses and office staff in Depts. VII, VIII, and IX for their helpfulness during my work.

I am indebted to the librarian of Ullevål Hospital, Miss Ingrid Kobro and her assistants for their help in procuring the literature.

To my wife I wish to express my warm gratitude for her great tolerance and for invaluable assistance in the preparation of this study.

I gratefully acknowledge financial support from Johan H. Andresen, J. L. Tiedemanns Tobaksfabrik's Medisinske Fond.

Finally I wish to thank Dr. Susan Schanche who has translated this paper from Norwegian to English.

Ullevål Hospital, Dept. VIII,
Oslo, Norway, January 1957.

Christopher Juel Bjerkelund

Contents.

Chapter I

Background to this study	13
------------------------------------	----

Chapter II

The problem of the investigation. Theoretical and practical considerations for the solution of the problem	15
Presentation of the problem and primary considerations	15
Pathogenesis of coronary occlusion	15
Incidence of thrombosis as the cause of coronary occlusion	16
Appositional growth of the thrombus	17
Recanalisation of thrombus	18
The role of intimal bleeding in the pathogenesis	18
Other pathogenetic factors	20
Is thrombosis a pathogenetic factor in the development of atherosclerosis?	20
Prognosis after survival from acute myocardial infarction	22
Discussion of previous investigations on the long term prognosis after myocardial infarction	22
Cause of death in coronary disease	25
Practical conditions for the investigation	26
Possibilities for collecting material	26
Basis for control of treatment with dicoumarol	27
Summary and conclusion	29

Chapter III

Previous publications on long term anticoagulant therapy	31
Account of previous publications	31
Haemorrhagic complications	38
Summary and conclusion	41

Chapter IV

Planning the investigation	43
Allotting patients to the treated and control groups	43
Choice of statistical method of selection	43
Question of the use of placebos	45
Age limit	46
Size of treated and control groups	46
Patients who had to be withdrawn from the final investigation	47
Clinical investigation of the patients while in hospital	47
Case history	47
Clinical examination	48
Investigations	48

Diagnosis of the acute infarct—diagnostic criteria	48
Investigation technique	49
Quantitative estimation of prothrombin-proconvertin. Owren's PP method	49
Quantitative estimation of total serum cholesterol	52
Liver function tests	52
Electrocardiographic technique	53
Radiological examination of the heart	53
Summary and conclusion	53

Chapter V

Selection of patients for the investigation	55
The total material—section A	55
Patients excluded from the controlled clinical trial according to plan	56
Additional patients excluded from the controlled clinical trial	57
Summary	59

Chapter VI

More details about the material. Statistical examination of the comparability of the treated and control groups	60
Introductory remarks	60
General characteristics of the sample	61
Age distribution	61
Sex distribution	62
Race	62
Geography	62
Social standing	62
Height and weight	63
Conditions in the previous history considered to be of significance for the prognosis	64
Angina pectoris	64
Myocardial infarction	64
Hypertension	65
Heart failure	66
Valvular disease	66
Cerebral vascular accident	67
Obliterating arteriosclerosis and thromboangiitis obliterans	67
Diabetes mellitus	68
Course of the recorded acute infarct	68
Prodromal symptoms of infarction	69
Attack at rest or on exertion?	69
Interval between attack and admission	70
Pain	70
Vomiting	71
Dyspnoea	71
Heart failure	72
Pericardial friction rub	73
Gallop rhythm	73
Maximum pulse rate in the first week	73
Blood pressure	74

Shock	77
Position of the myocardial infarct on electrocardiography	78
Arrhythmias and conduction disturbances	79
Maximum temperature during the first week	80
Leucocyte count	80
Blood sedimentation rate	81
Fasting blood sugar	82
Serum cholesterol, xanthelasma, xanthomatous nodules	83
Cardiac volume estimated radiologically	84
Summary and conclusion	86

Chapter VII

Treatment of the acute infarct during the first month	88
Medical care	88
Nursing	89
General care	89
Medical and dietetic treatment	90
Use of digitalis	90
Salt restriction	90
Restriction of calories	91
Use of oxygen	91
Treatment of shock by transfusion	91
Use of dicoumarol	91
Duration of treatment with dicoumarol in the control group	92
Use of heparin	93
Complications during treatment of the acute infarct	93
Haemorrhagic complications	94
Thromboembolic complications	94
Complications with no direct relationship to the heart or to anticoagulants	95
Length of time in hospital	96
Condition on discharge	97
Summary and conclusion	97

Chapter VIII

Observation and treatment in the ambulant phase. Length of observation	99
Management of the control group	99
Management of the treated group	101
Recording and filing the data	102
Management of treatment with dicoumarol	102
Length of observation	105
Summary and conclusion	106

Chapter IX

Intensity of the anticoagulant therapy as judged by the PP values recorded during the observation time	108
Introductory remarks	108
Relationship between the PP values recorded and the PP level over the total period of treatment	109
Interruptions in treatment	111